Skip to main content
An official website of the United States government
Email

Ipilimumab (YERVOY®)

Agent Description

Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa.

Mechanism of Action

CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T cell responsiveness, including the anti-tumor immune response.

Classification

Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86.

Molecular Target

N/A

Monograph

View the ipilimumab package insert (PDF).

Studies of Interest

Areas of Interest

Bladder: studies in various lines of therapy with nivolumab/ipilimumab plus standard of care (BCG, chemo)

Areas NOT of Interest

  • Ipilimumab monotherapy in metastatic melanoma patients (exception is ipilimumab in patients whose cancer progressed on anti-PD1)
  • Ipilimumab monotherapy in adjuvant stage 3 melanoma patients (exception is special populations like mucosal and uveal)
  • Ipilimumab combinations with standard of care in metastatic melanoma
  • Ipilimumab combinations with radiation in melanoma
  • Nivolumab/ipilimumab/cabozantinib combination in renal cell carcinoma

Information collaborator would like included in investigator proposals

N/A

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Ipilimumab (YERVOY®) was originally published by the National Cancer Institute.”

Email